When it comes to investing, sometimes thinking small is best, says Forbes' Yuval Bar-Or. Progress in technology and innovative products associated with DNA sequencing and the human genome could mean investment opportunities. As the $1,000 (or cheaper) genome approaches, the implications are "at once wondrous and disturbing," says Bar-Or, who hold investments in Illumina and Life Technologies.